Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.75 |
| ▸ | PDE3B | Q13370 | 13/20 | 0.75 |
| ▸ | PDE3A | Q14432 | 13/20 | 0.75 |
| ▸ | ABL1 | P00519 | 1/20 | 0.75 |
| ▸ | NQO2 | P16083 | 1/20 | 0.75 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.75 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.75 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.75 |
| ▸ | MAP3K19 | Q56UN5 | 1/20 | 0.75 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.75 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4252065 | 0.90 | MET (0.77) | METPDE3BPDE3AABL1NQO2 | |
| SCHEMBL15177005 | 0.89 | MET (0.76) | METPDE3BPDE3AABL1NQO2 | |
| SCHEMBL4255231 | 0.89 | MET (0.75) | METPDE3BPDE3AABL1NQO2 | |
| Sgx-523 SCHEMBL30222396 | 0.85 | MET (1.00) | METPDE3BPDE3AABL1NQO2 | |
| SCHEMBL4499219 | 0.85 | MET (0.76) | METPDE3BPDE3AABL1NQO2 | |
| Sgx-523 SCHEMBL29354539 | 0.85 | MET (1.00) | METPDE3BPDE3AABL1NQO2 | |
| Sgx-523 SCHEMBL4496422 | 0.85 | MET (1.00) | METPDE3BPDE3AABL1NQO2 | |
| SCHEMBL15177007 | 0.85 | MET (0.70) | METPDE3BPDE3AABL1NQO2 | |
| SCHEMBL509206 | 0.85 | MET (0.75) | METPDE3BPDE3AABL1NQO2 | |
| SCHEMBL15177004 | 0.83 | MET (0.70) | METPDE3BPDE3AABL1NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8507489-B2 | Bicyclic triazoles as protein kinase modulators | SGX PHARMACEUTICALS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| EP-2084162-B1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS INC (US) | 2012-09-12 | — | — | EP | disclosed |
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. | 2009-10-15 | — | — | US | disclosed |
| EP-2084162-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX Pharmaceuticals, Inc. (US) | 2009-08-05 | — | — | EP | disclosed |
| WO-2008051808-A2 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-05-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258855-A1 | BICYCLIC TRIAZOLES AS PROTEIN KINASE MODULATORS | MAP3K20, TTK, PRKACB | MET 1052/4885PDE3B 1674/4885PDE3A 1648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.